Swiss National Bank Grows Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Swiss National Bank increased its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 36.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 486,700 shares of the company’s stock after acquiring an additional 129,600 shares during the quarter. Swiss National Bank owned approximately 0.12% of Recursion Pharmaceuticals worth $3,290,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also bought and sold shares of the company. Farther Finance Advisors LLC grew its holdings in shares of Recursion Pharmaceuticals by 21.1% in the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company’s stock worth $52,000 after purchasing an additional 1,353 shares during the last quarter. HighTower Advisors LLC increased its position in shares of Recursion Pharmaceuticals by 408.5% in the fourth quarter. HighTower Advisors LLC now owns 122,770 shares of the company’s stock valued at $830,000 after acquiring an additional 98,626 shares during the period. Prosperity Wealth Management Inc. bought a new position in shares of Recursion Pharmaceuticals during the fourth quarter valued at about $257,000. Daiwa Securities Group Inc. boosted its holdings in shares of Recursion Pharmaceuticals by 28.3% during the fourth quarter. Daiwa Securities Group Inc. now owns 10,135 shares of the company’s stock worth $69,000 after purchasing an additional 2,235 shares during the period. Finally, PNC Financial Services Group Inc. grew its stake in shares of Recursion Pharmaceuticals by 220.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 9,820 shares of the company’s stock worth $66,000 after purchasing an additional 6,758 shares during the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Stock Performance

Shares of Recursion Pharmaceuticals stock opened at $6.17 on Thursday. Recursion Pharmaceuticals, Inc. has a 12 month low of $5.60 and a 12 month high of $12.36. The firm has a market capitalization of $2.48 billion, a P/E ratio of -4.03 and a beta of 0.85. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The business has a fifty day simple moving average of $7.47 and a two-hundred day simple moving average of $7.01.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). The business had revenue of $4.60 million for the quarter, compared to analysts’ expectations of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company’s revenue was down 57.8% on a year-over-year basis. During the same period last year, the business earned ($0.42) earnings per share. On average, equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. KeyCorp cut their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Thursday, February 6th. Cowen reaffirmed a “hold” rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Finally, Leerink Partners reduced their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a research report on Friday, February 28th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $8.25.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.